Past Events

Interested in understanding the journey from biomarker discovery to real-world healthcare applications? Researchers and innovators are invited to this insightful discussion on navigating the path from discovery to commercial success in the biomarker and diagnostics space.

Industry leaders and successful entrepreneurs will share practical insights on identifying commercially viable biomarkers, early-stage validation, test development, regulatory pathways, and integration into clinical practice. Whether you're considering commercialization or actively developing diagnostic solutions, this panel offers valuable perspectives on turning promising research into market-ready products.

Moderated by Iris Bica, a Business Development and Licensing Associate for the Center of Technology Licensing at Weill Cornell Medicine, the panel will feature:

• Dan Klass, Senior Director of Emerging Technologies, Freenome
• Marieke Spaan, Senior Director Corporate Development, SkylineDx
• Daniel Lunz, CEO & Co-Founder, Previse

Register now. 

This exciting program is designed to efficiently advance early stage projects, that have the potential to benefit patients, to proof of concept studies. Sanders TDI contributes medicinal chemistry and drug development capabilities that complement the deep scientific expertise already available in our research community.

The recipients of Sanders TDI support will be selected by a Request for Proposal (RFP) process. To select the most promising projects in the most unbiased manner possible, Sanders TDI draws upon a scientific advisory board (SAB) comprised of recognized scientific and thought leaders drawn from the biopharmaceutical industry, the venture capital community, and the faculty of WCMC, RU and MSKCC (for a list of members please see the About Sanders TDI web page: https://www.tritdi.org/leadership/). The SAB utilizes well-established, stringent criteria to select the most competitive and transformational projects for execution. The SAB also helps to oversee and assess progress of the selected projects, which are milestone-driven and designed to reach specified value-inflection points.

The project application is a three-step process:

1. Submission of a letter of intent (LOI) that includes a basic description of the project, describes the unmet medical need, and provides a scientific rationale the project. The Letter of Intent is due Thursday, Feb 13, 2025. 
2. A full application package (8-10 pages) that will be requested from PIs whose LOIs describe projects that fit well with the Sanders TDI mission.
3. Review of the application by the Sanders TDI Small Molecule Scientific Advisory Board.

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations.

Successful applicants will receive funding of up to $400,000 USD over 2 years.

Interested researchers are invited to:

• Attend information webinars to learn more about the initiative: Thursday, January 23 at 1pm ET or Wednesday, February 5, at 11am ET
• Contact James Bellush at jmb824@cornell.edu to express interest in applying and to obtain online application submission instructions.
• Submit a non-confidential, 300 word abstract via the CSL online application portal by February 20, 2025.

Ignite Connect: Accelerating Impact is a new signature event of the Ignite Cornell Lab to Market program series. This virtual event serves as a unique venue to connect investors, industry partners, and stakeholders with technology innovations and companies that have benefited from the Ignite Gap Funding Program. 

It is an opportunity to explore and engage with researchers and founders around their technologies and ventures emerging from Cornell University. This dynamic virtual experience aims to create connections and serves as a catalyst, bridging innovative technologies with resources and opportunities for meaningful impact.

Register now.